154 related articles for article (PubMed ID: 34503219)
21. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).
Mesnage SJL; Auguste A; Genestie C; Dunant A; Pain E; Drusch F; Gouy S; Morice P; Bentivegna E; Lhomme C; Pautier P; Michels J; Le Formal A; Cheaib B; Adam J; Leary AF
Ann Oncol; 2017 Mar; 28(3):651-657. PubMed ID: 27864219
[TBL] [Abstract][Full Text] [Related]
22. Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.
Sharma P; Barlow WE; Godwin AK; Parkes EE; Knight LA; Walker SM; Kennedy RD; Harkin DP; Logan GE; Steele CJ; Lambe SM; Badve S; Gökmen-Polar Y; Pathak HB; Isakova K; Linden HM; Porter P; Pusztai L; Thompson AM; Tripathy D; Hortobagyi GN; Hayes DF
J Clin Oncol; 2019 Dec; 37(36):3484-3492. PubMed ID: 31657982
[TBL] [Abstract][Full Text] [Related]
23. Standardized assessment of tumor-infiltrating lymphocytes in breast cancer: an evaluation of inter-observer agreement between pathologists.
Tramm T; Di Caterino T; Jylling AB; Lelkaitis G; Lænkholm AV; Ragó P; Tabor TP; Talman MM; Vouza E;
Acta Oncol; 2018 Jan; 57(1):90-94. PubMed ID: 29168428
[TBL] [Abstract][Full Text] [Related]
24. Why pathologists and oncologists should know about tumour-infiltrating lymphocytes (TILs) in triple-negative breast cancer: an Australian experience of 139 cases.
Fuchs TL; Pearson A; Pickett J; Diakos C; Dewar R; Chan D; Guminski A; Menzies A; Baron-Hay S; Sheen A; Sioson L; Chou A; Gill AJ
Pathology; 2020 Aug; 52(5):515-521. PubMed ID: 32553444
[TBL] [Abstract][Full Text] [Related]
25. Deep learning model improves tumor-infiltrating lymphocyte evaluation and therapeutic response prediction in breast cancer.
Choi S; Cho SI; Jung W; Lee T; Choi SJ; Song S; Park G; Park S; Ma M; Pereira S; Yoo D; Shin S; Ock CY; Kim S
NPJ Breast Cancer; 2023 Aug; 9(1):71. PubMed ID: 37648694
[TBL] [Abstract][Full Text] [Related]
26. Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer.
Kim RS; Song N; Gavin PG; Salgado R; Bandos H; Kos Z; Floris G; Eynden GGGMVD; Badve S; Demaria S; Rastogi P; Fehrenbacher L; Mamounas EP; Swain SM; Wickerham DL; Costantino JP; Paik S; Wolmark N; Geyer CE; Lucas PC; Pogue-Geile KL
J Natl Cancer Inst; 2019 Aug; 111(8):867-871. PubMed ID: 30888406
[TBL] [Abstract][Full Text] [Related]
27. Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer.
Hida AI; Watanabe T; Sagara Y; Kashiwaba M; Sagara Y; Aogi K; Ohi Y; Tanimoto A
Breast Cancer Res Treat; 2019 Nov; 178(2):283-294. PubMed ID: 31402409
[TBL] [Abstract][Full Text] [Related]
28. Inter- and Intra-Observer Agreement of PD-L1 SP142 Scoring in Breast Carcinoma-A Large Multi-Institutional International Study.
Zaakouk M; Van Bockstal M; Galant C; Callagy G; Provenzano E; Hunt R; D'Arrigo C; Badr NM; O'Sullivan B; Starczynski J; Tanchel B; Mir Y; Lewis P; Shaaban AM
Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900303
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of Tumor infiltrating lymphocytes in breast carcinoma and their correlation with molecular subtypes, tumor grade and stage.
Pujani M; Jain H; Chauhan V; Agarwal C; Singh K; Singh M
Breast Dis; 2020; 39(2):61-69. PubMed ID: 32310155
[TBL] [Abstract][Full Text] [Related]
30. Hotspot enumeration of CD8+ tumor-infiltrating lymphocytes using digital image analysis in triple-negative breast cancer yields consistent results.
McIntire PJ; Zhong E; Patel A; Khani F; D'Alfonso TM; Chen Z; Shin SJ; Ginter PS
Hum Pathol; 2019 Mar; 85():27-32. PubMed ID: 30381263
[TBL] [Abstract][Full Text] [Related]
31. Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial.
Abuhadra N; Sun R; Yam C; Rauch GM; Ding Q; Lim B; Thompson AM; Mittendorf EA; Adrada BE; Damodaran S; Virani K; White J; Ravenberg E; Sun J; Choi J; Candelaria R; Arun B; Ueno NT; Santiago L; Saleem S; Abouharb S; Murthy RK; Ibrahim N; Sahin A; Valero V; Symmans WF; Litton JK; Tripathy D; Moulder S; Huo L
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444385
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer.
Nederlof I; De Bortoli D; Bareche Y; Nguyen B; de Maaker M; Hooijer GKJ; Buisseret L; Kok M; Smid M; Van den Eynden GGGM; Brinkman AB; Hudecek J; Koster J; Sotiriou C; Larsimont D; Martens JWM; van de Vijver MJ; Horlings HM; Salgado R; Biganzoli E; Desmedt C
Breast Cancer Res; 2019 Dec; 21(1):151. PubMed ID: 31878981
[TBL] [Abstract][Full Text] [Related]
33. Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and its prognostic significance.
Althobiti M; Aleskandarany MA; Joseph C; Toss M; Mongan N; Diez-Rodriguez M; Nolan CC; Ashankyty I; Ellis IO; Green AR; Rakha EA
Histopathology; 2018 Dec; 73(6):887-896. PubMed ID: 29947077
[TBL] [Abstract][Full Text] [Related]
34. Training pathologists to assess stromal tumour-infiltrating lymphocytes in breast cancer synergises efforts in clinical care and scientific research.
Ly A; Garcia V; Blenman KRM; Ehinger A; Elfer K; Hanna MG; Li X; Peeters DJE; Birmingham R; Dudgeon S; Gardecki E; Gupta R; Lennerz J; Pan T; Saltz J; Wharton KA; Ehinger D; Acs B; Dequeker EMC; Salgado R; Gallas BD
Histopathology; 2024 May; 84(6):915-923. PubMed ID: 38433289
[TBL] [Abstract][Full Text] [Related]
35. Longitudinal Assessment of Tumor-Infiltrating Lymphocytes in Primary Breast Cancer Following Neoadjuvant Radiation Therapy.
Yoneyama M; Zormpas-Petridis K; Robinson R; Sobhani F; Provenzano E; Steel H; Lightowlers S; Towns C; Castillo SP; Anbalagan S; Lund T; Wennerberg E; Melcher A; Coles CE; Roxanis I; Yuan Y; Somaiah N
Int J Radiat Oncol Biol Phys; 2024 Apr; ():. PubMed ID: 38677525
[TBL] [Abstract][Full Text] [Related]
36. Reproducible evaluation of tumor-infiltrating lymphocytes (TILs) using the recommendations of International TILs Working Group 2014.
Kojima YA; Wang X; Sun H; Compton F; Covinsky M; Zhang S
Ann Diagn Pathol; 2018 Aug; 35():77-79. PubMed ID: 29886396
[TBL] [Abstract][Full Text] [Related]
37. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
38. High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients.
AiErken N; Shi HJ; Zhou Y; Shao N; Zhang J; Shi Y; Yuan ZY; Lin Y
Int J Biol Sci; 2017; 13(9):1172-1179. PubMed ID: 29104508
[TBL] [Abstract][Full Text] [Related]
39. Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration.
Leung SCY; Nielsen TO; Zabaglo LA; Arun I; Badve SS; Bane AL; Bartlett JMS; Borgquist S; Chang MC; Dodson A; Ehinger A; Fineberg S; Focke CM; Gao D; Gown AM; Gutierrez C; Hugh JC; Kos Z; Laenkholm AV; Mastropasqua MG; Moriya T; Nofech-Mozes S; Osborne CK; Penault-Llorca FM; Piper T; Sakatani T; Salgado R; Starczynski J; Sugie T; van der Vegt B; Viale G; Hayes DF; McShane LM; Dowsett M;
Histopathology; 2019 Aug; 75(2):225-235. PubMed ID: 31017314
[TBL] [Abstract][Full Text] [Related]
40. Programmed Death Ligand 1 Immunohistochemistry in Triple-Negative Breast Cancer: Evaluation of Inter-Pathologist Concordance and Inter-Assay Variability.
Ahn S; Woo JW; Kim H; Cho EY; Kim A; Kim JY; Kim C; Lee HJ; Lee JS; Bae YK; Kwon Y; Kim WS; Park SY
J Breast Cancer; 2021 Jun; 24(3):266-279. PubMed ID: 34128367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
